Hamlet BioPharma

Bladder cancer is a significant unmet medical need and the costliest cancer form in the USA, due to high recurrence rates and cancer progression. Despite available treatments, patient remain at risk of recurrence, creating a need for less toxic therapies.  The Phase III study is based on an extensive scientific and clinical evaluation of Alpha1H by the FDA (Food and Drug Administration, USA), including reviews of published clinical data and the mechanism of action described in peer-reviewed publications.

"Despite advances in bladder cancer treatment, recurrence remains a major challenge for many patients. Based on our evaluation of Alpha1H and the clinical results generated to date, we believe the treatment warrants further investigation in the neo-adjuvant setting. We look forward to exploring the potential of Alpha1H to improve outcomes for patients with bladder cancer", says Marek Babjuk, Professor of Urology and Dean of the Medical School at the Charles University in Prague.

"The Phase III trial represents an important step in our clinical and commercial development. The Phase III study collaboration with the Prague team and Professor Babjuk allows us to evaluate Alpha1H in this patient population with longer follow up and comparisons to the standard of care", says Catharina Svanborg, Professor at Lund University and Chairman of the Board of Hamlet BioPharma.

For further information, please contact

Catharina Svanborg, Chairman of the Board, Hamlet BioPharma AB, +46 709 42 65 49,

catharina.svanborg@hamletpharma.com

Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10,

jakob.testad@hamletbiopharma.com

www.hamletbiopharma.com